Acute leukemias that bear chromosomal translocations at 11q23 possess rearrangements of the Mixed Lineage Leukemia gene (MLL, HRX, ALL-1). More than 40 different MLL translocations have been reported, but the t(9;11) (MLL-AF9) and the t(4;11) (MLL-AF4) are particularly common. MLL-AF9 is most frequently identified in leukemias diagnosed as AML whereas MLL-AF4 is found solely in leukemias diagnosed as ALL or mixed-lineage leukemia. Patients with MLL-AF4 rearranged leukemias have a poor prognosis. This is particularly true for infant leukemia where approximately 80% of cases will harbor rearrangement of the MLL gene. We have previously demonstrated that human lymphoblastic leukemias harboring MLLrearrangements possess a unique gene expression profile that suggests they arise from an early hematopoietic progenitor. This approach also identified the receptor tyrosine kinase FLT3 as a potential therapeutic target in this disease. Using a murine model system of MLL-AF9 induced AML, we have recently identified a hematopoietic stem cell (HSC) associated gene expression program activated in granulocyte macrophage progenitors (GMP) during their conversion to leukemia stem cells (LSC). In these studies we noted repression of cebp/a as a component of the MLL-AF9 induced program.
In specific aim 1 we will asses specific genes found highly expressed in LSC, and perform a high-throughput screen to identify small molecules that reverse the LSC program.
In specific aim 2 of this proposal we will work with members of project 3 to interrogate the role of cebp/a in MLL-rearranged leukemia.
In specific aim 3 we will work with members of projects 1 and 2 to develop a conditional murine model of MLL-AF4 induced leukemia and assess the potential for cooperation with mutant FLT3 alleles during leukemogenesis. Such a model will not only allow identification of progenitor populations susceptible to MLL-AF4 induced transformation, but also provide a much-needed model for assessment of therapeutics developed in projects 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-13
Application #
8063510
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
13
Fiscal Year
2010
Total Cost
$536,418
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Gutierrez-Martinez, Paula; Hogdal, Leah; Nagai, Manavi et al. (2018) Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol 20:413-421
Gooptu, Mahasweta; Kim, Haesook T; Chen, Yi-Bin et al. (2018) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant 24:2216-2223
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:29-43.e7
Nabet, Behnam; Roberts, Justin M; Buckley, Dennis L et al. (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499
Hshieh, Tammy T; Jung, Wooram F; Grande, Laura J et al. (2018) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 4:686-693
Sellar, Rob S; Jaiswal, Siddhartha; Ebert, Benjamin L (2018) Predicting progression to AML. Nat Med 24:904-906
Montero, Joan; Letai, Antony (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ 25:56-64
Patel, Sanjay S; Kuo, Frank C; Gibson, Christopher J et al. (2018) High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood 131:2816-2825

Showing the most recent 10 out of 376 publications